|
COMMERCE BUSINESS DAILY ISSUE OF JUNE 1,2000 PSA#2612NCI Frederick Cancer Research and Development Center (NCI-FCRDC), P.O.
Box B, Frederick, Maryland 21702-1201 A -- CGMP PRODUCTION OF PEPTIDES SOL S00-170 DUE 061300 POC Thomas L.
Danver, Sr. Contract Specialist at 301-846-5422; Terry W. Hebb, Sr.
Contracts Advisor at 301-846-5416 E-MAIL: Click here to contact the
contract specialist via, tdanver@mail.ncifcrf.gov. The National Cancer
Institute's (NCI) new Rapid Access To Intervention Development program
(RAID) program is designed to utilize NCI contract resources to assist
extramural investigators with the preclinical and clinical development
requirements for drugs and biologics that will be used in clinical
trials. As part of this new initiative, the NCI wishes to identify
qualified Offerors, who can produce clinical-grade peptides from 4-50
mers in length, for use in clinical trials. As part of this new
initiative, the NCI wishes to find new contract resources that are
capable of manufacture, purification, formulation, and vialing of
peptides under current Good Manufacturing Practices (cGMP) appropriate
for Phase I/II clinical trials. The NCI will provide the sequence of
the desired peptide(s). In addition, the NCI will provide information
on the formulation and vialing requirements of all products. Offerors
should have experience in the cGMP manufacturing and vialing of
clinical-grade peptides for clinicaltrials. The contractor will be
required to provide a Certificate Of Analysis (COA), that provides data
that support the identity, composition, purity, potency, and safety of
the requested products. In addition, the NCI should have the
opportunity to cross-reference the contractor=s Drug Master File for
IND purposes. Interested companies should describe their capabilities
and experience and respond by June 13, 2000 to Thomas L. Danver. Posted
05/26/00 (W-SN459384). (0147) Loren Data Corp. http://www.ld.com (SYN# 0009 20000601\A-0009.SOL)
A - Research and Development Index Page
|
|